Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Extension of Convertible Loan Note with CFR International SpA
Allergy Therapeutics plc, the fully integrated specialty pharmaceutical company, announces that CFR International SpA and the Company have agreed to extend the term of the £4.04 million convertible loan made available to the Company on 30 March 2012. The date of maturity of the convertible loan has been extended from 20 April 2014 to 30 September 2014. All other terms for the Convertible Loan remain unchanged.
Ends-
For further information
|
Allergy Therapeutics |
+44 (0) 1903 845 820 |
|
Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director |
|
|
Peel Hunt LLP |
+44 (0) 20 7418 8900 |
|
James Steel Clare Terlouw |
|
|
FTI Consulting |
+44 (0) 20 3727 1000 |
|
Simon Conway Victoria Foster Mitchell |
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of almost £40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.
This information is provided by RNS